No information is available on the clinical use of resmetirom during breastfeeding. Because resmetirom is more than 99% bound to plasma proteins, the amount in milk is likely to be low. If the mother requires resmetirom, it is not a reason to discontinue breastfeeding. Until more data are available, resmetirom should be used with careful infant monitoring during breastfeeding, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Resmetirom
CAS Registry Number
920509-32-6
Drug Class
Breast Feeding
Lactation
Milk, Human
Thyroid Hormone Receptor-Beta Agonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
